Anti-Human CD134 (OX40) PE 25 tests
- Known as:
- Antibody toHuman CD134 (OX40) PE 25 tests
- Catalog number:
- 12-1347-41
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD134 (OX40) 25 tests
Related genes to: Anti-Human CD134 (OX40) PE 25 tests
- Gene:
- TNFRSF4 NIH gene
- Name:
- TNF receptor superfamily member 4
- Previous symbol:
- TXGP1L
- Synonyms:
- ACT35, OX40, CD134
- Chromosome:
- 1p36.33
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-15
- Date modifiied:
- 2019-04-23
Related products to: Anti-Human CD134 (OX40) PE 25 tests
Related articles to: Anti-Human CD134 (OX40) PE 25 tests
- Diet is a modifiable determinant of aging. We develop and validate the Machine-learning YouTHful (MYTH) Diet, a dietary pattern associated with reduced aging-related mortality. Using data from 191,689 participants in the UK Biobank, we conducted a food-wide association analysis and identified 18 food groups significantly associated with aging-related mortality. A Light Gradient Boosting Machine (LightGBM) model was used to rank food importance, leading to the construction of a 10-component MYTH Diet score (range: 0-10). Higher MYTH scores were consistently associated with reduced aging-related mortality in both internal (Quartile 4 vs. 1: hazard ratio [HR] = 0.79; 95% CI: 0.75-0.84) and external (Q4 vs. Q1: HR = 0.68; 95% CI: 0.58-0.80) validation cohorts. Multi-omics analyses revealed that the diet's protective effects were partly mediated through proteomic, metabolic, and inflammatory pathways, with mediators including TNFRSF4, the proportion of polyunsaturated fatty acids (PUFA%), and lipid-related metabolites such as medium very-low-density lipoprotein phospholipids (M-VLDL-PL). Higher MYTH scores were also linked to slower biological aging in the lungs, liver, pancreas, as well as lower risks for 15 aging-related diseases. These findings suggest that the MYTH Diet may offer a biologically informed, scalable framework for developing personalized nutrition strategies aimed at supporting healthy aging and longevity. - Source: PubMed
Publication date: 2026/08/07
Miao YatingLi ZhirongZhang XinyaoLiu ZuyunMa Yanan - - Source: PubMed
Publication date: 2026/08/25
Komatsu-Fujii TakayoshiAsahina RyotaHasegawa TatsuyaNakamizo SatoshiNakajima SaekoKogame ToshiakiKabashima Kenji - The important roles of T cells in tumor progression support the development of a T cell-associated prognostic model for Head and Neck Squamous Cell Carcinoma (HNSCC). - Source: PubMed
Publication date: 2026/08/13
Shi QingmiaoQi ZhenzhenShang BingyangGeng XiaonanZhang ZhiboHuang DiHu Xinjun - The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance. - Source: PubMed
Publication date: 2026/08/03
Wang QianyuTian NaGuo HanchuanXiang YingshiXiao YiLin GuoleZhang GuannanXu LaiLu JunyangChen GangCai HuiyunDu XiaohuiDu JunfengWu Bin - : Laryngeal squamous cell carcinoma (LSCC) is a highly aggressive malignancy with poor prognosis, particularly in advanced stages. While traditional treatments have improved survival rates, reliable biomarkers for prognosis remain limited. : We analyzed RNA-seq data of LSCC patients from the Cancer Genome Atlas (TCGA) and validated the results using the Gene Expression Omnibus (GEO) dataset (GSE27020), clinical samples, and LSCC cell lines. Differentially expressed immune-related genes (DEIRGs) were identified using the "limma" R package. A prognostic signature was developed by integrating univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox analysis. The signature's predictive performance was validated using Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curves. : A three-gene immune-related prognostic signature comprising TNFRSF4, PPARG, and PDGFA was established. In the training cohort, the model stratified patients into high- and low-risk groups with significantly different overall survival (HR = 5.81, 95% CI: 2.56-13.22, < 0.001), with apparent 1-, 2-, and 3-year AUC values of 0.838, 0.895, and 0.947, respectively. Predictive performance was further evaluated in the TCGA testing cohort, the full TCGA cohort, and the GSE27020 cohort. Functional enrichment analysis revealed that the signature genes are involved in immune regulation and tumor progression. : This study identified and validated a novel three-gene immune-related prognostic signature for LSCC, offering a practical tool for individualized prognosis and personalized treatment strategies. The signature provides insights into immune-related mechanisms in LSCC, presenting potential targets for therapeutic intervention. - Source: PubMed
Publication date: 2026/07/09
He ChangdingPeng WanqiuShi YiDu Huaidong